Daniel Gorovets, MD
Radiation Oncology · New York, NYNPI 1639431992
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $843 of the $1,135 with a category attached, or 74.3%. Novartis accounts for 77.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $1,006 and has fallen 98.3% since, to $17 in 2025.
Across 12 payments — averaging $94.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$882
- Boston Scientific$96
- Teleflex LLC$57
- Sumitomo Pharma America, Inc.$37
- Blue Earth Diagnostics$26
- Pfizer$22
- plus $16 from 1 others
Across 5 payments — averaging $26,240 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$131K
What the payments were for
- Travel & lodging$29226%
- Food & beverage$84374%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $882 |
| Boston Scientific | 1 | $96 |
| Teleflex LLC | 3 | $57 |
| Sumitomo Pharma America, Inc. | 1 | $37 |
| Blue Earth Diagnostics | 1 | $26 |
| Pfizer | 1 | $22 |
| Myovant Sciences Inc. | 1 | $16 |
How this compares
$1,135 in reported general payments places this provider in the 70th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 32 | $80,944 |
| Tamsulosin Hcl | 55 | $603 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $448 |
| Ciprofloxacin Hcl | 16 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $37 | $80,94432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 397 radiation oncology providers in New York.
Other radiation oncology in New York
- Michael ZelefskyNew York$946K
- Nancy LeeNew York$233K
- Robert SamsteinNew York$125K
- Jalal AhmedNew York$100K
- Charles SimoneNew York$84K
- Silvia FormentiNew York$57K
- Brandon ImberNew York$44K
- Himanshu NagarNew York$43K
- Chiaojung TsaiNew York$38K
- Christopher BarkerNew York$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.